Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-07-12

FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Div of Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NEURONTIN (gabapentin)

Snippet

SUPPL AP for NEURONTIN (GABAPENTIN)